Amgen Company Profile (NASDAQ:AMGN)

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen announced a quarterly dividend on Friday, July 28th. Shareholders of record on Thursday, August 17th will be given a dividend of $1.15 per share on Friday, September 8th. This represents a $4.60 annualized dividend and a yield of 2.51%. The ex-dividend date of this dividend is Tuesday, August 15th. View Amgen's Dividend History.

Amgen Inc. (NASDAQ:AMGN) released its quarterly earnings data on Tuesday, July, 25th. The company reported $3.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.84 EPS. View Amgen's Earnings History.

Amgen is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Amgen.

Amgen updated its FY17 earnings guidance on Monday, September, 25th. The company provided earnings per share guidance of $12.15-12.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $12.56. The company issued revenue guidance of $22.5-23.0 billion, compared to the consensus revenue estimate of $22.85 billion.

20 equities research analysts have issued 12-month price targets for Amgen's stock. Their forecasts range from $161.00 to $210.00. On average, they expect Amgen's stock price to reach $191.06 in the next twelve months. View Analyst Ratings for Amgen.

Here are some recent quotes from research analysts about Amgen stock:

• 1. According to Zacks Investment Research, "Amgen is well positioned for growth with several blockbuster drugs in its portfolio. Amgen’s newer drugs – Prolia, Xgeva, Vectibix, Nplate and Sensipar – are all performing well. Additionally, Amgen’s restructuring plan should make it leaner and more cost efficient. Amgen is also progressing with its pipeline, including biosimilar drugs. Amgen’s shares have outperformed the industry so far this year. However, the company has some challenges in store, given the presence of biosimilar competition and slowdown in sales of mature products. Volume growth of new drugs may not be enough to offset lost sales due to the decline in mature brands. Meanwhile, uptake of Repatha has been slow due to payer restrictions. Estimates have gone up ahead of the company’s Q3 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (10/16/2017)
• 2. Cann analysts commented, "Amgen yesterday announced that the Journal of Clinical Oncology has published positive results from the Imlygic (talimogene laherparepvec) phase II ‘264 study, demonstrating a doubling of response rate or better in the Imlygic combination arm. The data published yesterday in JCO are encouraging, and these along with results from ongoing studies could lead to unexpected adoption of Imlygic and provide upside to our sales estimates. These data demonstrated that Imlygic has a dramatic effect in combination with Yervoy, and the combination looks as strong a much of the reference data for other combinations." (10/6/2017)
• 3. Mizuho analysts commented, "We are increasing our AMGN price target from $183 to $198 on the back of the biotech sector having re-rated somewhat post the GILD/KITE acquisition. We have not changed our estimates." (9/28/2017)
• 4. Cowen and Company analysts commented, "Amgen reported Q1 Revenue of $5.46B (-1% Y/Y, vs. consensus of $5.61BE) and." (4/27/2017)
• 5. BMO Capital Markets analysts commented, "We expect the overall survival (OS) benefit in relapsed myeloma patients to enable Kyprolis to grow in the face of generic competition for Velcade. Upside, however, is in our opinion dependent on data in combination with Revlimid+dex (ECOG Ph3) in newly-diagnosed patients given failure of CLARION. Anecdotal data suggests that Darzalex is best suited in IMiD and proteasome inhibitor failures given lack of response of these agents in patients failing Darzalex." (3/6/2017)

Amgen saw a increase in short interest in September. As of September 15th, there was short interest totalling 9,412,565 shares, an increase of 29.5% from the August 31st total of 7,267,419 shares. Based on an average daily volume of 3,016,948 shares, the short-interest ratio is currently 3.1 days. Approximately 1.3% of the shares of the company are sold short.

Some companies that are related to Amgen include Pfizer (PFE), Novartis AG (NVS), Merck & Company (MRK), Novo Nordisk A/S (NVO), Sanofi (SNY), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Celgene Corporation (CELG), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY) and Catalent (CTLT).

Amgen's management team includes the folowing people:

• Robert A. Bradway, Chairman of the Board, President, Chief Executive Officer
• David W. Meline, Executive Vice President, Chief Financial Officer
• Sean E. Harper, Executive Vice President - Research and Development
• Anthony C. Hooper, Executive Vice President - Global Commercial Operations
• Brian M. McNamee, Executive Vice President - Full Potential Initiatives
• Esteban Santos, Executive Vice President, Operations
• Cynthia M. Patton, Senior Vice President, Chief Compliance Officer
• Jonathan P. Graham, Senior Vice President, General Counsel, Secretary
• Lori A. Johnston, Senior Vice President
• David A. Piacquad, Senior Vice President - Business Development

Amgen's stock is owned by many different of retail and institutional investors. Top institutional investors include APG Asset Management N.V. (0.22%), PGGM Investments (0.10%), State Treasurer State of Michigan (0.03%), Hermes Investment Management Ltd. (0.03%), Oakbrook Investments LLC (0.03%) and Douglas Lane & Associates LLC (0.02%). Company insiders that own Amgen stock include Annette Louise Such, Cynthia M Patton, David Baltimore, Madhavan Balachandran and Sean E Harper. View Institutional Ownership Trends for Amgen.

Amgen's stock was sold by a variety of institutional investors in the last quarter, including Douglas Lane & Associates LLC, State Treasurer State of Michigan, Bridges Investment Counsel Inc., Oakbrook Investments LLC, Viking Fund Management LLC, Wealth Enhancement Advisory Services LLC, Private Asset Management Inc. and LS Investment Advisors LLC. Company insiders that have sold Amgen stock in the last year include Cynthia M Patton and Sean E Harper. View Insider Buying and Selling for Amgen.

Amgen's stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Hermes Investment Management Ltd., PGGM Investments, APG Asset Management N.V., Meeder Asset Management Inc., Carnick & Kubik Group LLC, Balasa Dinverno & Foltz LLC and Financial Advisory Service Inc.. View Insider Buying and Selling for Amgen.

Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Amgen stock can currently be purchased for approximately $182.96.